Rehmann Capital Advisory Group’s Achillion Pharmaceuticals ACHN Stock Holding History

Rehmann Capital Advisory Group’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$3.99K	Hold	1,109	–	–	﹤0.01%	1268
2019 Q2	$2.97K	Hold	1,109	–	–	﹤0.01%	1687
2019 Q1	$3.28K	Hold	1,109	–	–	﹤0.01%	1632
2018 Q4	$1.76K	Hold	1,109	–	–	﹤0.01%	1499
2018 Q3	$4.08K	Hold	1,109	–	–	﹤0.01%	1606
2018 Q2	$3.14K	Hold	1,109	–	–	﹤0.01%	1673
2018 Q1	$4K	Buy	+1,109	New	+$3.63K	﹤0.01%	1601

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Rehmann Capital Advisory Group's ACHN Position: Q3 2019 in Review

Rehmann Capital Advisory Group held its Achillion Pharmaceuticals (ACHN) position steady in Q3 2019 at 1,109 shares worth $3.99K. The position accounts for ﹤0.01% of the portfolio, ranked #1268.

Rehmann Capital Advisory Group first reported a position in ACHN in Q1 2018 and has held it in 7 quarters since. The position peaked at $4.08K in Q3 2018. 122 funds tracked by Wall St. Rank hold ACHN as of Q3 2019.

Rehmann Capital Advisory Group held 1,109 shares of Achillion Pharmaceuticals worth $3.99K as of Q3 2019.
Rehmann Capital Advisory Group left its Achillion Pharmaceuticals share count unchanged in Q3 2019.
Achillion Pharmaceuticals made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1268 holding.
Rehmann Capital Advisory Group first reported a position in Achillion Pharmaceuticals in Q1 2018 and has held it in 7 quarters since.
Rehmann Capital Advisory Group's Achillion Pharmaceuticals position peaked at $4.08K in Q3 2018.
122 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.